New therapies for castrate-resistant prostate cancer

被引：3

作者：

Williams, Stephen B. ^{[1
]}

Lay, Aaron H. ^{[1
]}

Lau, Clayton S. ^{[2
]}

Josephson, David Y. ^{[2
]}

Wilson, Timothy G. ^{[2
]}

Choueiri, Toni K. ^{[3
]}

Pal, Sumanta K. ^{[4
]}

机构：

[1] Harvard Univ, Brigham & Womens Hosp, Div Urol, Sch Med, Boston, MA 02115 USA

[2] City Hope Comprehens Canc Ctr, Div Urol Oncol, Dept Urol, Duarte, CA 91010 USA

[3] Harvard Univ, Lank Ctr Genitourinary Oncol, Dana Farber Canc Inst, Sch Med, Boston, MA 02115 USA

[4] City Hope Comprehens Canc Ctr, Div Genitourinary Malignancies, Dept Med Oncol & Expt Therapeut, Duarte, CA 91010 USA

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2011年 / 12卷 / 13期

关键词：

castrate resistant; chemotherapy; outcomes; prostate cancer; review; MITOXANTRONE PLUS PREDNISONE; I CLINICAL-TRIAL; ABIRATERONE ACETATE; ANTITUMOR-ACTIVITY; DOCETAXEL; CYP17; INHIBITOR; IMMUNOTHERAPY; ANTIANDROGEN; CHEMOTHERAPY;

D O I：

10.1517/14656566.2011.590133

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Introduction: Prostate cancer is the second leading cause of cancer death in men in the USA, and most of these deaths will occur as a result of castrate-resistant prostate cancer (CRPC) that has progressed despite androgen deprivation therapy. There has been better understanding of castration resistance and molecular mechanisms of prostate cancer progression recently, leading to new treatment strategies. Areas covered: This review focuses on emerging and new therapies for castrate-resistant prostate cancer, including hormonal therapy, immunotherapy and cytotoxic agents. Expert opinion: New treatment strategies have been developed in recent years and, with improved understanding of advanced CRPC, additional targeted treatments are expected in the near future. Further cost effectiveness research of these treatments is warranted before dissemination of these promising agents.

引用

页码：2069 / 2074

页数：6

共 50 条

[31] Enzalutamide in treatment of castrate-resistant prostate cancer
Zolnierek, Jakub
[J]. ONCOLOGY IN CLINICAL PRACTICE, 2014, 10 (03): : 148 - 151
[32] Castrate-resistant prostate cancer: therapeutic strategies
Harzstark, Andrea L.
Small, Eric J.
[J]. EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (06) : 937 - 945
[33] Zibotentan for the treatment of castrate-resistant prostate cancer
Shepard, Dale R.
Dreicer, Robert
[J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2010, 19 (07) : 899 - 908
[34] Reappraisal of glucocorticoids in castrate-resistant prostate cancer
Sartor, Oliver
Parker, Christopher C.
De Bono, Johann
[J]. ASIAN JOURNAL OF ANDROLOGY, 2014, 16 (05) : 666 - 666
[35] Castrate-resistant prostate cancer: postdocetaxel management
Zhao, Song
Yu, Evan Y.
[J]. CURRENT OPINION IN UROLOGY, 2013, 23 (03) : 201 - 207
[36] Pharmacotherapeutic strategies for castrate-resistant prostate cancer
Moussa, Mohamad
Papatsoris, Athanasios
Abou Chakra, Mohamed
Sryropoulou, Despoina
Dellis, Athanasios
[J]. EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (12) : 1431 - 1448
[37] Novel Antiandrogen Therapies in Patients with Castrate-Resistant Prostate Cancer: A Tertiary Institution Experience
Lee, S-F
[J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 63 - 63
[38] Testosterone Therapy in Castrate-Resistant Prostate Cancer: A Possible New Approach
Gardiner, Robert A.
Sweeney, Christopher
Tilley, Wayne D.
[J]. EUROPEAN UROLOGY, 2009, 56 (02) : 245 - 246
[39] Metastatic castrate-resistant prostate cancer: dawn of a new age of management
Masson, Susan
Bahl, Amit
[J]. BJU INTERNATIONAL, 2012, 110 (08) : 1110 - 1114
[40] Emerging new drugs and regimens for castrate-resistant prostate cancer (CRPC)
Sartor, Oliver
[J]. INTERNATIONAL JOURNAL OF UROLOGY, 2015, 22 (04) : 427 - 427

← 1 2 3 4 5 →